The public health value of vaccines beyond efficacy: methods, measures and outcomes
Assessments of vaccine efficacy and safety capture only the minimum information needed for regulatory approval, rather than the full public health value of vaccines. Vaccine efficacy provides a measure of proportionate disease reduction, is usually limited to etiologically confirmed disease, and foc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 July 2017
|
| In: |
BMC medicine
Year: 2017, Jahrgang: 15, Pages: 1-9 |
| ISSN: | 1741-7015 |
| DOI: | 10.1186/s12916-017-0911-8 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s12916-017-0911-8 Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12916-017-0911-8 
|
| Verfasserangaben: | A. Wilder-Smith, I. Longini, P. L. Zuber, T. Bärnighausen, W. J. Edmunds, N. Dean, V. Masserey Spicher, M. R. Benissa and B. D. Gessner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576239977 | ||
| 003 | DE-627 | ||
| 005 | 20220814160738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180611s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12916-017-0911-8 |2 doi | |
| 035 | |a (DE-627)1576239977 | ||
| 035 | |a (DE-576)506239977 | ||
| 035 | |a (DE-599)BSZ506239977 | ||
| 035 | |a (OCoLC)1341011296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wilder-Smith, Annelies |e VerfasserIn |0 (DE-588)1064971458 |0 (DE-627)815377339 |0 (DE-576)186940998 |4 aut | |
| 245 | 1 | 4 | |a The public health value of vaccines beyond efficacy |b methods, measures and outcomes |c A. Wilder-Smith, I. Longini, P. L. Zuber, T. Bärnighausen, W. J. Edmunds, N. Dean, V. Masserey Spicher, M. R. Benissa and B. D. Gessner |
| 264 | 1 | |c 26 July 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.02.2022 | ||
| 520 | |a Assessments of vaccine efficacy and safety capture only the minimum information needed for regulatory approval, rather than the full public health value of vaccines. Vaccine efficacy provides a measure of proportionate disease reduction, is usually limited to etiologically confirmed disease, and focuses on the direct protection of the vaccinated individual. Herein, we propose a broader scope of methods, measures and outcomes to evaluate the effectiveness and public health impact to be considered for evidence-informed policymaking in both pre- and post-licensure stages. | ||
| 650 | 4 | |a Cluster randomised controlled trial | |
| 650 | 4 | |a Dynamic modelling | |
| 650 | 4 | |a Effectiveness | |
| 650 | 4 | |a Overall effectiveness | |
| 650 | 4 | |a Post-licensure | |
| 650 | 4 | |a Pre-licensure | |
| 650 | 4 | |a Public health impact | |
| 650 | 4 | |a Quasi-experiments | |
| 650 | 4 | |a Vaccine efficacy | |
| 650 | 4 | |a Vaccine-preventable disease incidence | |
| 700 | 1 | |a Bärnighausen, Till |d 1969- |e VerfasserIn |0 (DE-588)120262029 |0 (DE-627)080560512 |0 (DE-576)178470848 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC medicine |d London : BioMed Central, 2003 |g 15(2017), Artikel-ID 138, Seite 1-9 |h Online-Ressource |w (DE-627)377271225 |w (DE-600)2131669-7 |w (DE-576)121906655 |x 1741-7015 |7 nnas |a The public health value of vaccines beyond efficacy methods, measures and outcomes |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g elocationid:138 |g pages:1-9 |g extent:9 |a The public health value of vaccines beyond efficacy methods, measures and outcomes |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12916-017-0911-8 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12916-017-0911-8 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180611 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 120262029 |a Bärnighausen, Till |m 120262029:Bärnighausen, Till |d 910000 |d 912800 |e 910000PB120262029 |e 912800PB120262029 |k 0/910000/ |k 1/910000/912800/ |p 2 | ||
| 998 | |g 1064971458 |a Wilder-Smith, Annelies |m 1064971458:Wilder-Smith, Annelies |d 910000 |d 912800 |d 50000 |e 910000PW1064971458 |e 912800PW1064971458 |e 50000PW1064971458 |k 0/910000/ |k 1/910000/912800/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1576239977 |e 3012401598 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 02.02.2022"],"name":{"displayForm":["A. Wilder-Smith, I. Longini, P. L. Zuber, T. Bärnighausen, W. J. Edmunds, N. Dean, V. Masserey Spicher, M. R. Benissa and B. D. Gessner"]},"language":["eng"],"title":[{"subtitle":"methods, measures and outcomes","title":"The public health value of vaccines beyond efficacy","title_sort":"public health value of vaccines beyond efficacy"}],"physDesc":[{"extent":"9 S."}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"26 July 2017"}],"id":{"doi":["10.1186/s12916-017-0911-8"],"eki":["1576239977"]},"recId":"1576239977","relHost":[{"id":{"eki":["377271225"],"zdb":["2131669-7"],"issn":["1741-7015"]},"origin":[{"publisher":"BioMed Central ; Springer","dateIssuedDisp":"2003-","dateIssuedKey":"2003","publisherPlace":"London ; Berlin ; Heidelberg [u.a.]"}],"note":["Gesehen am 29.10.13"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"BMC medicine","title_sort":"BMC medicine"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"377271225","disp":"The public health value of vaccines beyond efficacy methods, measures and outcomesBMC medicine","part":{"text":"15(2017), Artikel-ID 138, Seite 1-9","year":"2017","extent":"9","volume":"15","pages":"1-9"},"pubHistory":["1.2003 -"]}],"person":[{"role":"aut","display":"Wilder-Smith, Annelies","family":"Wilder-Smith","given":"Annelies"},{"given":"Till","role":"aut","family":"Bärnighausen","display":"Bärnighausen, Till"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a WILDERSMITPUBLICHEAL2620 | ||